Xalabrands Refresher

Which of the following describes

latanoprost, the active ingredient in

XALATAN?

• PGH2 antagonist

• PGE2 analogue

• PGF2 analogue

• PGI2 antagonist

XALATAN reduces IOP by:

• increasing the outflow of aqueous

  humor.

• inhibiting the production of aqueous

  humor by the ciliary body.

• causing reabsorption of aqueous humor.

• preventing the circulation of aqueous

  humor into the anterior chamber.

In a clinical trial of latanoprost designed to

assess iris pigmentation over 5 years, there

was evidence of several adverse

consequences due to increased

pigmentation.

• True

• False

Latanoprost should be used with caution in

patients with which of the following?

• Ocular hypertension

• history of low blood pressure

• open angle glaucoma

• history of herptic keratitis

Xalatan is stored

• Store unopened bottle
  under refrigeration at
  2°C to 8°C

• Opened bottle may be
  stored at room temperature
  up to 25°C

• Unopened bottle may be
  stored at room temperature
  up to 25°C

• Opened bottle
  under refrigeration at
  2°C to 8°C

The Timolol maleate component of

XALACOM belongs to what drug class?

• Prostaglandin analogues

• Beta adrenergic receptor agonists

• Prostaglandin antagonists

• B adrenergic receptor blockers

The Timolol maleate component of

XALACOM is thought to reduce IOP by:

• Increasing the outflow of aqueous

  humor

• Inhibiting the formation of aqueous

  humor by the ciliary body

• Causing reabsorption of aqueous humor

• preventing the circulation of aqueous

  humor into the anterior chamber

Timolol maleate has significant intrinsic

sympathomimetic, direct myocardial

depressant, and local anesthetic activity.

• True

• False

Which of the following is (are)

contraindications to XALACOM?

• Peripheral circulatory disorders

• Known hypersensitivity to latanoprost,

  Timolol maleate, or any component of

  the product

• Reactive airway disease

• Microbial infection of any kind

The adverse reactions associated with

systemic administration of beta adrenergic

blocking agents are not a concern when

they are administered topically, as with the

Timolol component of XALACOM.

• True

• False